RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.

<h4>Background/objectives</h4>KRAS-mutant lung adenocarcinoma remains without effective targeted therapies for most patients, particularly those with non-G12C alleles or resistance to KRASG12C inhibitors. RAF1 is essential for KRAS-driven tumor maintenance through kinase-independent survival functio...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Laura de-la-Puente-Ovejero, Ana Fernández-Rodríguez, Sarah Francoz, Gonzalo Aizpurua, Lucía Lomba-Riego, Matthias Drosten, Carmen Guerra, Mónica Musteanu, Mariano Barbacid, Sara García-Alonso
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Public Library of Science (PLoS) 2026-01-01
Edice:	PLoS ONE
On-line přístup:	https://doi.org/10.1371/journal.pone.0341778
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!